Two chemotherapy approaches for advanced prostate cancer

Plain-English translation of NCT06738303 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether — two chemotherapy drugs given together — work better than 177Lu-PSMA-617, a radioactive treatment that targets cancer cells. The study focuses on men with aggressive prostate cancer that has progressed despite previous hormone-based treatments. Researchers want to learn which approach helps patients live longer and with fewer side effects.

Advanced prostate cancer that stops responding to hormone therapy is very serious, with patients living on average less than three years. Although several treatments exist, doctors don't yet know which is best for each patient, and many men don't respond well to current options. This trial will help determine the optimal choice of treatment for men in this situation.

Do you qualify?

You likely qualify if…

you have been diagnosed with metastatic castrate-resistant prostate cancer (cancer that has spread and stopped responding to hormone therapy)
you have previously received at least one hormone-based therapy and your cancer has progressed
you have a PET scan showing your cancer cells light up, indicating they express PSMA (a protein targeted by the treatments)
you have evidence of aggressive disease, such as spread to organs like the lungs or liver, or five or more bone metastases
you have adequate organ function and blood cell counts, as measured by blood tests
you are 18 years or older and able to understand and sign the informed consent form

You likely don't qualify if…

you have hormone-sensitive prostate cancer (cancer that still responds to hormone therapy)
you have a rare type of prostate cancer called small cell carcinoma
you are currently taking other investigational (experimental) cancer medications
you have been diagnosed with another cancer in the past 2 years
you have severely impaired kidney, liver, or bone marrow function

What participation looks like

You will be randomly assigned to receive one of two treatments. If you receive , you will come to the clinic every three weeks for chemotherapy infusions lasting about one hour, for up to 10 cycles (about 30 weeks). If you receive 177Lu-PSMA-617, you will have infusions every six weeks for up to 6 cycles (about 36 weeks). Throughout the trial, you will have blood tests and imaging scans to monitor how well the treatment is working and to check for side effects.

AI-generated summary from trial data · Aug 21, 2026 · Not medical advice

Trial locations(1 site)

United States

Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio